Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

ACADIA Pharmaceuticals Inc (ACAD-RM)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
ACADIA historical data, for real-time data please try another search
1,300.00 0.00    0.00%
25/02 - Real-time Data. Currency in RUB ( Disclaimer )
Type:  Equity
Market:  Russia
ISIN:  US0042251084 
  • Volume: 0
  • Bid/Ask: 1,258.00 / 1,999.00
  • Day's Range: 1,258.00 - 1,300.00
ACADIA 1,300.00 0.00 0.00%

ACADIA Pharmaceuticals Inc Company Profile

 
Get an in-depth profile of ACADIA Pharmaceuticals Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryBiotechnology & Medical Research
SectorHealthcare
Employees

598

Equity Type

ORD

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome. It also develops Pimavanserin that is in Phase III ADVANCE-2 study to treat the negative symptoms of schizophrenia; ACP-101 whixh is in Phase III for the treatment of hyperphagia in Prader-Willi syndrome; ACP-204 which is in Phase II for the treatment of Alzheimer’s disease psychosis; ACP-2591 that is in Phase I for Rett syndrome and Fragile X syndrome; preclinical antisense oligonucleotide programs; and other programs for neuropsychiatric symptoms. It has a license agreement with Neuren Pharmaceuticals Limited to develop and commercialize trofinetide for Rett syndrome and other indications; and a license and collaboration agreement with Stoke Therapeutics, Inc. to discover, develop and commercialize novel RNA-based medicines for the potential treatment of severe and rare genetic neurodevelopmental diseases of the CNS. The company was formerly known as Receptor Technologies, Inc. and changed its name ACADIA Pharmaceuticals Inc. in 1997. ACADIA Pharmaceuticals Inc. was incorporated in 1993 and is headquartered in San Diego, California.

Contact Information

Address 12830 El Camino Real Suite 400
San Diego, 92130
United States
Phone 858 558 2871
Fax 858 212 0513

Top Executives

Name Age Since Title
Paul S. Anderson 85 - Member of the Scientific and Clinical Advisory Board
Daniel B. Soland 68 2015 Independent Director
Stephen R. Davis 63 2014 President, CEO & Director
Arvid Carlsson 101 - Member of the Scientific and Clinical Advisory Board
Stephen R. Biggar 53 2013 Independent Chairman of the Board
Carol A. Tamminga - - Member of the Scientific and Clinical Advisory Board
Laura A. Brege 66 2008 Independent Director
Julian Charles Baker 57 2015 Independent Director
Elizabeth A. Garofalo 65 2020 Independent Director
Edmund P. Harrigan 71 2015 Independent Director
James M. Daly 62 2016 Independent Director
Adora Ndu 43 2022 Independent Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

ACAD Comments

Write your thoughts about ACADIA Pharmaceuticals Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Cyrus Cyrus
Cyrus Cyrus Jun 23, 2022 10:17AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Mashallaha
Chijioke Nweke
Chijioke Nweke Aug 20, 2021 3:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
what is going on
Nitesh Chaudhari
Nitesh Chaudhari Jun 25, 2021 1:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Thuyii78857ujuuoukho0ojmBnmnmnBjjkjkBnjkh
St onks
St onks Jun 10, 2021 1:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
eh il wait til we trading above bollinger band to short, much safer
St onks
St onks Jun 10, 2021 1:22PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
woops wrong board
Rod All
Rod All May 30, 2021 9:25PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
slow ride to the moon but worth the wait
Rod All
Rod All May 23, 2021 9:03PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
going to the moon
Davis Davis
Davis Davis May 18, 2021 10:41AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
get back to 50 please
St onks
St onks May 10, 2021 3:27PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
4197 close imo
joninge kvamme
joninge kvamme Mar 16, 2021 1:29PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
A italian journalist predict a new clinical trail for the sustrate. This will take time i suppose.
joninge kvamme
joninge kvamme Mar 15, 2021 4:01PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Somebody knows something.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email